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Background
Lung cancer is the leading cause of malignancy-related death around the world. Non-
small cell lung cancer (NSCLC) accounts for more than 85  % of all lung cancer cases 
and its five-year overall survival (OS) rate approximates 15  % in both developed and 
developing countries (Jemal et al. 2011; Alberg et al. 2013; Efird et al. 2014). The mor-
bidity and mortality rates have dramatically increased in both male and female patients 
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with lung cancer during the last decade (Hoffman et al. 2000; Ferlay et al. 2010; Wu et al. 
2013). According to WHO’s estimations, China will become one of the countries with 
relatively higher prevalence of NSCLC in this century. Advanced pathological staging, 
early metastasis and poor response to treatments are the potential leading causes for a 
poor prognosis of NSCLC. To improve clinicians’ decisions on appropriate therapeutic 
regimens and patient managements, it has been increasingly urgent to identify strong 
biomarkers that can accurately predict the clinicopathological characteristics and prog-
nostic outcomes of NSCLC.
A great number of clinical and experimental researches have focused on the prognostic 
factors in NSCLC and identified many possible biomarkers. Heat shock proteins (HSPs) 
are a group of highly conserved proteins with essential hemostatic functions under phys-
iological conditions and protective functions under stressful conditions (Haslbeck et al. 
2005). Heat shock protein 27 (HSP27) encoded by HSPB1 is an important representative 
of the HSP family (Guo et al. 2010). Previous investigations have provided the increasing 
evidences indicating that HSP27 can be an effective predictor for many diseases, includ-
ing renal injury and fibrosis, cancers, neurological degeneration and cardiovascular dis-
eases (Vidyasagar et al. 2012). Its prognostic roles have been demonstrated in some solid 
tumors such as head-cervical carcinomas and colorectal cancers (Norton et  al. 2010; 
Kaigorodova and Bogatyuk 2014). Although there have been studies attempted to clarify 
the clinicopathological and prognostic significances of HSP27 in NSCLC, some contro-
versial and even totally contradictory results have appeared, resulting in that no con-
sensus has been reached until now (Vidyasagar et al. 2012; Kaigorodova and Bogatyuk 
2014).
Therefore, we performed the current systematic review and meta-analysis to help 
addressing this issue. First, we aim to evaluate the relationship between HSP27 expres-
sion and major clinicopathological characteristics of NSCLC. Second, we investigated 
the prognostic value of HSP27 on survival outcomes in patients with NSCLC. Based on 
applying the evidence-based methods to a larger number of enrolled samples, this meta-




No protocol had been previously published for this review. A meta-analysis does not 
require necessary patients’ consent or ethical approval. We performed this meta-analy-
sis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (Moher et al. 2009). An additional PRISMA checklist is 
given in the Additional file 1.
Search strategies
No language or publication data restriction was imposed within this meta-analysis. Four 
universal electronic databases, including PubMed, EMBASE (via Ovid interface), the 
Web of Science (via campus network of Sichuan University) and China National Knowl-
edge Infrastructure (CNKI), were selected for identifications of eligible literatures. Three 
search strings were combined with several key words and Boolean Operators (“AND” 
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and “OR”). These key words involved the “heat shock protein 27”, “heat shock protein 
B1”, “HSP27”, “HSPB1”, “lung cancer”, “lung carcinoma” and “lung neoplasm”. The com-
plete searching details were outlined in the Additional file 2. We also manually searched 
the reference lists of relevant literatures to identify any one possibly included study with 
no duplication.
Inclusion and exclusion criteria
The following eligibility criteria was established to determine the eligible studies 
included into our meta-analysis.
Inclusion criteria: (I) the target disease is NSCLC, not involving small cell lung can-
cer (SCLC) or other lung malignances; (II) positive expression of HSP27 is indepen-
dently detected, not in accompany with other biomarkers; (III) demographic details and 
Kaplan–Meier (K–M) survival curves assessing the prognostic roles of HSP27 and its 
relationship to major clinicopathological features of NSCLC are available in the original 
articles, and the endpoint prefers to be the OS; (IV) outcome statistics indicating the 
prognostic significance of HSP27, including the odds ratio (OR), hazard ratio (HR) and 
relative risk (RR), are directly reported in the original articles.
Exclusion criteria: (I) the following literature styles should be immediately excluded, 
including reviews, letters, laboratorial experiments and conference abstracts; (II) valid 
data correlated with the HSP27 expression in NSCLC were not reported; (III) the com-
parisons of HSP27 expression between carcinomatous tissues and normal tissues of the 
lung are not considered.
Quality assessment
Newcastle-Ottawa Scale (NOS) was applied to evaluate the quality of original non-
randomized studies (Stang 2010). Three perspectives including selection, comparability 
and exposure were considered for estimations of the quality and potential bias risks. The 
“star system” with a maximum of 9 stars was employed as the assessment tool. After 
grading all of the included studies, we regarded 8–9 stars as a good quality, 6–7 stars as a 
fair quality, and lower than 6 stars as a poor quality.
Data collection
We designed an Microsoft Office Excel spreadsheet to record the following details: (I) 
publication data including authors, publication year and nations; (II) experimental data 
including study design, study period, investigating fields, detecting materials and meth-
ods, cut-off values and follow-ups; (III) demographic data including enrolled samples, 
the number of patients with positive expression and negative expression of HSP27; (IV) 
statistical data including statistical methods, outcome statistics with the corresponding 
95  % confidence interval (95  % CI) and their sources, including those extrapolated by 
demographic and survival data or just directly reported from the original articles.
Statistical analysis
To evaluate the association between HSP27 expression and clinicopathological charac-
teristics in patients with NSCLC, we determined to adopt the OR with 95 % CI as the 
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appropriate summarized statistics. If HR or RR derived from multivariate analysis was 
reported, we could immediately incorporate it into the meta-analysis (Li et al. 2016b).
To assess the prognostic value of HSP27 expression in patients with NSCLC, HR with 
95 % CI was determined to serve as the summarized estimates because that HR was gen-
erally regarded as the only statistical value compatible for both censoring and time-to-
events (Parmar et al. 1998). It would be an optimal way to incorporate the multivariate 
HR outcomes into the meta-analysis because that multivariate analysis using logistic 
regression or Cox proportional hazards model was generally used to eliminate the bias 
risks from other confounding factors in observational studies. If no multivariate statistic 
was reported, we could extrapolate univariate HR with 95 % CI from the survival data 
according to a practical method described by Tierney et al. (2007). The relevant formulas 
are given as follows:
where O−E is the log rank Observed minus Expected events and V is the log rank Vari-
ance (Tierney et al. 2007). Then, we could extract the survival data by Engauge Digitizer 
4.1 (http://sourceforge.net) from the K–M curves to measure the accuracy of estimated 
HR. In addition, the multivariate RR and OR could be considered as HR and incorpo-
rated into our meta-analysis (Li et al. 2016b).
Both Cochrane Q-test and I2-statistic were applied to estimate the level of heteroge-
neity within this meta-analysis. Fine heterogeneity was defined as I2 < 50 % and P > 0.1, 
and a fixed-effect model was employed at the same time. On the contrary, a random-
effect model would be selected if a significant heterogeneity was revealed by I2 ≥ 50 % or 
P ≤ 0.1 (Higgins and Thompson 2002).
Sensitivity analysis was also conducted to examine the stability of integrated estimates 
by omitting the individual study sequentially. The strong robustness of our meta-analysis 
would be confirmed if there were no substantial variation between the adjusted summa-
rized statistics and primary summarized statistics (Higgins et al. 2003).
Potential publication bias was detected by both Begg’s test and Egger’s test. Its pres-
ence was suggested by the symmetry of funnel plot conducted by Begg’s test, and in 
which log ORs and log HRs were plotted against their corresponding standard errors 
(SEs) (Begg and Mazumdar 1994). The significant bias was also suggested by Egger’s P 
value <0.05.
Finally, we declared that all of the above statistical analyses were accomplished by 
STATA 12.0 (STATA Corporation, College Station, TX).
O−E =
√
Total observed events × Analyzed research× Analyzed control(




Z score for P value/2
)
V =
Total observed events × Analyzed research× Analyzed control(
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Results
The selection of included studies
There were a total of 1495 publication items identified by searching through the four 
electronic databases, including 280 citations in PubMed, 143 citations in EMBASE, 
516 citations in the Web of Science and 556 citations in CNKI. There were 858 of them 
entered into the initial filtration after excluding the duplicated ones. The initial filtration 
was based on screening the titles and abstracts, while further filtration was conducted 
by reading through the full-text of remaining literatures. Then, ten full-text articles were 
identified for the possible eligibility in this meta-analysis (Huang et al. 2005; Liu et al. 
2016; Malusecka et al. 2008; Tsai et al. 2014; Wang et al. 2011; Yao et al. 2009; Zhao et al. 
2014a). Finally, all of these 10 articles were determined to be included into our meta-
analysis, including seven English papers (Huang et al. 2005; Liu et al. 2016; Malusecka 
et al. 2008; Tsai et al. 2014; Wang et al. 2011; Yao et al. 2009; Zhao et al. 2014a) and three 
Chinese papers (Li et al. 2005; Zhao et al. 2009; Zu and Huang 2005). The main proce-
dures and relevant details of above retrievals were shown as a PRISMA diagram (Fig. 1).
The quality level of included studies
The quality level of each study was estimated by a NOS score, then listed by the number 
of stars (Table 1). Finally, their mean score was 7.4 (ranged from 6 to 8), suggesting a 
fairly good quality level of all the included studies.
The characteristics of included studies
Baseline characteristics for these ten eligible articles were summarized in Table 1. Actu-
ally, there were 13 retrospective observational studies reported from these 10 papers, 
including 8 of them assessing the relationship between HSP27 expression and clinico-
pathological features of NSCLC (Huang et al. 2005; Liu et al. 2016; Wang et al. 2011; Yao 
et al. 2009; Zhao et al. 2009, 2014a; Li et al. 2005; Zu and Huang 2005) and 5 of them 
exploring the prognostic significance of HSP27 expression for OS of NSCLC patients 
(Liu et  al. 2016; Malusecka et  al. 2008; Tsai et  al. 2014; Wang et  al. 2011; Zhao et  al. 
2014a). Totally, 854 patients diagnosed with NSCLC were enrolled from the 13 included 
studies, and the sample size ranged from 22 to 209. Most researchers prepared paraffin-
embedded tissues as the experimental materials (Huang et  al. 2005; Wang et  al. 2011; 
Zhao et al. 2014a; Malusecka et al. 2008; Liu et al. 2016; Li et al. 2005; Zhao et al. 2009; 
Zu and Huang 2005), except the remaining two studies used the frozen tissues for further 
analysis (Tsai et al. 2014; Yao et al. 2009). Immunohistochemistry (IHC) was applied for 
the detection of positive expression of HSP27 among 12 studies except only one using 
the quantitative RT-PCR (Tsai et al. 2014). However, the positive-staining sites of HSP27 
and their corresponding cut-off definitions varied across different studies (Table 1). On 
the basis of such concerns, the positive expression rate of HSP27 was 61.4 % (524/854) in 
all of the NSCLC cases.
None of all the included studies supplied any statistic estimating the association 
between HSP27 expression and clinicopathological characteristics of NSCLC. However, 
valid demographics with the corresponding P value were reported within all of these 
studies. As for the prognostic value of HSP27, two studies directly reported the mul-
tivariate HR outcomes for 1-year OS (Malusecka et  al. 2008; Tsai et  al. 2014) and the 
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other three studies just provided the survival data with log-rank P value to assess the 
prognostic value of HSP27 for 5-year OS in NSCLC (Liu et al. 2016; Wang et al. 2011; 
Zhao et al. 2014a). In addition, the other statistical details of these ten eligible articles, 
including statistical analysis methods, outcome statistics and their extractions, were also 
summarized in Table 1.
Association between HSP27 expression and clinicopathological characteristics of NSCLC
We collected the demographic data from each included study to extrapolate the corre-
sponding OR with 95  % CI revealing the frequency of HSP27 expression on different 
clinicopathological variables. These parameters involved genders, ages, smoking status, 
differentiation degrees, histological subtypes, TNM stages, lymphatic metastasis and 
Fig. 1 PRISMA flow diagram of the literature retrieval. HSP27, heat shock protein 27; NSCLC, non-small cell 
lung cancer; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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tumor size. By pooling these ORs with 95 % CI of each clinicopathological variable, we 
found that positive expression of HSP27 was significantly associated with the lower dif-
ferentiation degree (OR 2.309; 95 % CI 1.645–3.242; P < 0.001; I2 = 0.0 %, p = 0.644; 
Fig.  2a; Table  2), lymphatic metastasis (OR 1.425; 95  % CI 1.040–1.953; P  =  0.027; 
I2  =  50.8  %, p  =  0.047; Fig.  2b; Table  2), advanced TNM stage (OR 2.10; 95  % CI 
1.134–3.888; P = 0.018; I2 = 54.8 %, p = 0.065; Fig. 2c; Table 2), squamous cell carci-
noma (SCC) (OR 1.827; 95 % CI 1.171–2.849; P = 0.008; I2 = 33.0 %, p = 0.214; Fig. 2d; 
Table 2) and larger tumor size (OR 1.949; 95 % CI 1.112–3.416; P = 0.020; I2 = 0.0 %, 
p = 0.858; Fig. 2e; Table 2). Thus, positive expression of HSP27 seems to be significantly 
correlated with the worse pathological characteristics of NSCLC. However, the summa-
rized outcomes indicated that HSP27 expression had no significant relationships with 
the clinical characteristics including gender (OR 1.099; 95 % CI 0.629–1.920; P = 0.740; 
I2 = 48.8 %, p = 0.069; Fig. 3a; Table 2), age (OR 1.125; 95 % CI 0.637–1.986; P = 0.685; 
I2 = 0.0 %, p = 0.570; Fig. 3b; Table 2) and smoking status (OR 1.246; 95 % CI 0.812–
1.913; P = 0.314; I2 = 0.0 %, p = 0.434; Fig. 3c; Table 2).
Fig. 2 Pooled analyses for assessing the associations between HSP27 expression and a differentiation 
degree, b lymphatic metastasis, c TNM stage, d histological subtypes and e tumor size of NSCLC. HSP27 heat 
shock protein 27, NSCLC non-small cell lung cancer
Page 10 of 19Li et al. SpringerPlus  (2016) 5:1165 
Prognostic value of HSP27 expression for OS in patients with NSCLC
On the one hand, the pooled HR for 1-year OS based on two included studies 
(Malusecka et  al. 2008; Tsai et  al. 2014) was 0.885 (95  % CI 0.140–5.599; P  =  0.896; 
I2 = 91.5 %, p = 0.001; Fig. 4a; Table 3), indicating that there was no significant correla-
tion between HSP27 expression and 1-year OS of NSCLC. On the other hand, the inte-
grated estimates for 5-year OS based on three included studies (Liu et al. 2016; Wang 
et al. 2011; Zhao et al. 2014a) suggested that HSP27 expression significantly predicted 
a worse prognosis in patients with NSCLC (HR: 1.832; 95 % CI 1.322–2.538; P < 0.001; 
I2 = 39.6 %, p = 0.191; Fig. 4b; Table 3). Moreover, further assessment of the association 
between HSP27 expression and long-term survival outcomes (10-year OS) was given up 
because of the scarcity of included studies and available results.
Sensitivity analysis
We conducted further sensitivity analysis and additional adjustments in both the evalua-
tions for clinicopathological and prognostic significance of HSP27 expression in NSCLC 
(the derived forest plots not shown). Finally, very high heterogeneity was only observed 
between two studies (Malusecka et al. 2008; Tsai et al. 2014) evaluating the relationship 
between HSP27 expression and 1-year OS (I2 = 91.5 %, p = 0.001). Both of the primary 
HR outcomes from these two studies were out of the estimated range by omitting each 
one study, respectively. Thus, the primary pooled data suggesting no significant cor-
relation between HSP27 expression and 1-year OS might not be reliable enough. The 
strong robustness of our meta-analyses for other clinicopathological characteristics and 
Table 2 Meta-analysis of  the clinicopathological significance of  HSP27 expression 
in patients with NSCLC
AC adenocarcinoma, CI confidence interval, HSP27 heat shock protein 27, N reference count, NE negative expression, NSCLC 




N No. samples Heterogeneity 
(I-squared, p)
Model OR with 95 % CI P value Conclusion
Total PE NE
Gender (male vs 
female)
7 654 383 271 48.8 %, 0.069 Random 1.099 (0.629–
1.920)
0.740 Not significant
Age (≥60 years 
vs <60 years)









(G3 vs G1 and 
G2)






8 714 426 288 50.8 %, 0.047 Random 1.425 (1.040–
1.953)
0.027 Significant
TNM stage (III/IV 
vs I/II)




types (SCC vs 
AC)






2 259 138 121 0.0 %, 0.858 Fixed 1.949 (1.112–
3.416)
0.020 Significant
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Fig. 3 Pooled analyses for assessing the associations between HSP27 expression and a gender, b age, and c 
smoking status in patients with NSCLC. HSP27 heat shock protein 27, NSCLC non-small cell lung cancer
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Fig. 4 Pooled analyses for assessing the prognostic value of HSP27 expression for a 1-year OS and b 5-year 
OS in patients with NSCLC. HSP27 heat shock protein 27, NSCLC non-small cell lung cancer; OS overall survival
Table 3 Meta-analyses of the prognostic value of HSP27 expression in patients with NSCLC
CI confidence interval, HR hazard ratio, HSP27 heat shock protein 27, N reference count, NE negative expression, NSCLC non‑
small cell lung cancer, OS overall survival, PE positive expression
Survival out-
comes
N No. samples Heterogeneity 
(I-squared, p)
Model HR (95 % CI) P value Conclusion
Total PE NE
1-year OS 2 140 98 42 91.5 %, 0.001 Random 0.885 (0.140–
5.599)
0.896 Not significant
5-year OS 3 334 185 149 39.6 %, 0.191 Fixed 1.832 (1.322–
2.538)
<0.001 Significant
10-year OS Given up because of the scarcity of included studies
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prognostic value of HSP27 expression for 5-year OS of NSCLC was confirmed by further 
sensitivity analysis.
Publication bias
There was no evidence for potential publication bias within the present meta-analysis. 
The funnel plots derived from Begg’s test were not showed but their corresponding Egg-
er’s and Begg’s P values were outlined in Table 4. Remarkably, we must warn about the 
poor efficacies of both Begg’s test and Egger’s test when including far less than 20 stud-
ies. Although no significant publication bias was revealed in our study, a poor sensitivity 
of both Begg’s test and Egger’s test should be seriously concerned because of the scarcity 
of enough included studies.
Discussion
Meta-analysis is a well-designed statistical method integrating the common outcome 
data from homogeneous studies to settle global conclusions on a pending issue (Zhu 
et al. 2016; Song et al. 2016; Kubo et al. 2015; Li et al. 2015, 2016a, b, c). To the best of 
our knowledge, this is the first comprehensive meta-analysis to determine the associa-
tion between HSP27 expression and major clinicopathological features of NSCLC, and 
the prognostic roles of HSP27 in NSCLC. On the one hand, our meta-analysis showed 
that HSP27 expression was significantly associated with worse pathological character-
istics of NSCLC, including poor differentiation degree, lymphatic metastasis, advanced 
TNM stage, SCC and larger tumor size. However, no association was observed between 
HSP27 expression and other clinical variables, including age, gender and smoking sta-
tus. On the other hand, positive expression of HSP27 significantly predicted the worse 
5-year OS in patients with NSCLC. However, there was no prognostic value of HSP27 
expression on 1-year OS of NSCLC based on the pooled analysis. Potential prognostic 
roles of HSP27 for long-time survival could not be estimated because of the scarcity of 
the currently available evidences.
Table 4 Assessments for the potential publication bias within the meta-analysis
AC adenocarcinoma, CI confidence interval, HR hazard ratio, OR odds ratio, OS overall survival, SCC squamous cell carcinoma
Groups of outcomes N Estimates Begg’s test  
(p value)




 Gender (male vs female) 7 OR with 95 % CI 1.0 0.410 Not significant
 Age (≥60 years vs <60 years) 3 OR with 95 % CI 1.0 0.645 Not significant
 Smoking status (yes vs no) 3 OR with 95 % CI 1.0 0.985 Not significant
 Differentiation degree  
(G3 vs G1 and G2)
8 OR with 95 % CI 0.322 0.120 Not significant
 Lymphatic metastasis  
(yes vs no)
8 OR with 95 % CI 0.322 0.160 Not significant
 TNM stage (III/IV vs I/II) 5 OR with 95 % CI 0.806 0.400 Not significant
 Histological subtypes  
(SCC vs AC)
4 OR with 95 % CI 1.0 0.309 Not significant
 Tumor size (≥3 cm vs <3 cm) 2 OR with 95 % CI 1.0 Not reported Not significant
Prognostic significance
 1-year OS 2 HR with 95 % CI 1.0 Not reported Not significant
 5-year OS 3 HR with 95 % CI 1.0 0.564 Not significant
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HSPs are firstly discovered in 1962 (Sadikovic et al. 2008). The following laboratorial 
investigations have clarified the universal responses of HSPs to hyperthermia and other 
physiological stresses in almost all cell types (Vidyasagar et al. 2012; Kaigorodova and 
Bogatyuk 2014). HSP27 belongs to the small HSP family with a molecular weight about 
12–43 kDa (Kim et al. 1998). It is generally regarded as a protein chaperone preventing 
the irreversible oligomerization and inducing the refolding of damaged proteins (Rogalla 
et  al. 1999). Cytoplasmic HSP27 has some protective effects on the stress conditions, 
such as oxidative stress and chemical stress. Arrigo et al. (2005) has described the anti-
oxidation function of cytoplasmic HSP27 by increasing intracellular glutathione level 
and decreasing intracellular iron level. Reactive oxygen species are largely controlled by 
the inhibitions from HSP27. As for chemical stress, many preclinical studies have identi-
fied the anti-apoptotic functions of HSP27 achieved by interacting with both mitochon-
dria dependent and independent pathways of apoptosis (Kaigorodova and Bogatyuk 
2014). On the basis of these discoveries, Nakashima et al. (2011) recognized the impact 
of HSP27 phosphorylation status on gemcitabine-induced growth suppression of pan-
creatic cancer. Hansen et  al. (1999) demonstrated that HSP27 could serve as an anti-
apoptotic agent during doxorubicin-induced apoptosis of human breast cancer cells, and 
indicated the inhibition of HSP27 expression in certain breast cancer chemotherapies. 
However, the latest study reported by Li et al. (2014) showed that the anti-tumor drug 
bufalin could trigger apoptosis by targeting HSP27 and it might become a novel thera-
peutic agent for pancreatic cancer. The underlying molecular mechanisms have not been 
well understood by now and more fundamental researches are required in the future.
HSP27 nuclear localization has been found to regulate the expression of gene control-
ling mRNA degradation and cell differentiation in erythrocytes (de Thonel et al. 2010; 
Li et al. 2013). Sedlackova et al. (2011) investigated the corresponding mRNA profiles of 
HSP27 and attempted to demonstrate the functions of HSP27 as a biomarker for differ-
entiation states. However, a limited sample size may cause negative effects on dissecting 
the correlation and lead to the observation of no diagnostic or prognostic value. Serum 
concentration of HSP27 in both chronic obstructive pulmonary disease and NSCLC was 
firstly studied by a research team from Austria (Zimmermann et al. 2012, 2014; Hacker 
et al. 2009; Ankersmit et al. 2015). Zimmermann et al. (2012) conducted a multi-institu-
tional case–control study to assess the potentially diagnostic value of HSP27 in NSCLC. 
Their outcome data suggested that serum HSP27 levels could be considered as an effec-
tive tool to discriminate between early and advanced stages of NSCLC, and COPD was 
the leading risk factor for NSCLC. Such diagnostic roles of circulating HSP27 was fur-
ther proved in their next study with 40 NSCLC cases and 40 healthy controls by different 
enzyme-linked immunosorbent assays (Zimmermann et al. 2014). Moreover, Schweiger 
et al. (2015) from the same Austrian team also argued that HSP27 was highly expressed 
in the tumor stroma of colorectal cancers (CRCs) and might play crucial roles in the pro-
jection of life duration in patients with pulmonary metastasis from CRCs, suggesting its 
potentially prognostic value in CRCs. It will be of great interest to bring above important 
discoveries into the realm of clinics to help to present a biomarker that can significantly 
predict the development of NSCLC (Ankersmit et al. 2015). Because of the limited sam-
ple availability in the current studies, a consensus based on a larger number of patients 
needs to be drawn in the future.
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Given above reviews, some clinical reports have attempted to reveal a potentially 
prognostic significance of HSP27 expression in many cancers, such as esophageal cancer 
(Xue et al. 2014), ovarian cancer (Zhao et al. 2014b), etc. As for the issue we concerned, 
both two relevant reviews accomplished by Vidyasagar et al. (2012) and Kaigorodova and 
Bogatyuk (2014) proposed the possible prognostic roles of HSP27 in NSCLC, but totally 
contradictory conclusions were finally drawn. It seems that these inconsistent results 
cannot be well-interpreted and there remains a controversy on the relationship between 
HSP27 expression and the prognosis of NSCLC. We recognized that the incomplete ref-
erences describing the prognostic value of HSP27 in NSCLC might largely reduce the 
accuracy of summarized outcomes. The differences in prognostic indicators could also 
cause adverse effects on reaching a consensus on the prognostic value of HSP27. Thus, 
in our meta-analysis, we integrated all of the currently available evidences together to 
achieve comprehensive and detailed assessments.
Systematic searching four electronic databases made us identify a total of five full-text 
papers focusing on the prognostic value of HSP27 in NSCLC. The earliest study per-
formed by Malusecka et  al. (2008) using multivariate analysis indicated that HSP27 
expression could predict the survival of NSCLC patients. Their outcome data revealed 
a significantly longer survival time in patients with positive HSP27 expression signals 
although only 1-year OS and 3-year OS were available (P = 0.003). Similarly, Tsai et al. 
(2014) also performed a survival analysis in 64 NSCLC patients and estimated the prog-
nostic significance of HSP27 for 1-year OS. However, a significantly worse prognosis in 
patients with positive expression of HSP27 was finally observed at the endpoint of fol-
low-up (P = 0.04). As for 5-year OS, two retrospective studies were conducted based on 
a larger sample size. The largest one reported by Zhao et al. (2014a) enrolled 209 NSCLC 
patients and compared the 5-year OS in patients with positive HSP27 expression and 
those with negative expression. Finally, a significantly higher survival rate appeared in 
the cohorts with negative HSP27 expression (55.9 vs 34.5 %, P = 0.003). Such predictive 
value of HSP27 for 5-year OS was also supported by what Liu et al. (2016) reported in 
their latest study with 22 adenocarcinoma cases. Wang et al. (2011) also carried out a 
survival analysis among 103 NSCLC cases, although no evidence was finally conducted 
for a significant correlation between HSP27 expression and 5-year OS. No previously 
associated studies revealing the predictive significance of HSP27 expression for 10-year 
OS were reported. We speculate that the very low 10-year OS of NSCLC patients itself 
may cause the lack of available analysis, especially in some observational studies based 
on a small number of enrolled patients.
Therefore, we classified the outcome data of these five studies into two groups to eval-
uate the prognostic values of HSP27 for 1-year OS and 5-year OS, respectively. Finally, 
high HSP27 expression was found to be significantly associated with the lower 5-year 
OS, indicating that HSP27 can be a strong biomarker predicting the worse 5-year OS 
of NSCLC. However, no significant relationship was observed between HSP27 expres-
sion and 1-year OS, and a remarkable heterogeneity (I2 =  91.5  %, p =  0.001) existed 
between studies. Our findings suggested two possible reasons causing such huge differ-
ences between 1-year OS group and 5-year OS group: (I) the larger sample size might 
contribute to figure out the prognostic value of HSP27 for 5-year OS rather than 1-year 
OS. The derived data might show stable changes with the increase of sample size; (II) 
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the potential impact of different adjuvant therapies on NSCLC patients might cause a 
variety of survival outcomes during different follow-up periods. There was evidence sug-
gesting that HSP27 overexpression in NSCLC tissues might significantly induce patients’ 
tolerance to chemotherapeutic agents if treated for a long time (Ciocca and Calderwood 
2005). Thus, the prognosis of NSCLC might be influenced by the different responses to 
adjuvant therapies with the prolongation of follow-up period. The poor responses to 
treatment could cause adverse effects on the OS of NSCLC (Tsai et al. 2014). Although 
many possible molecular mechanisms have been recently proposed, the correct one still 
needs to be clarified by further studies.
In addition, we compared the HSP27 expression in patients with different clinico-
pathological characteristics of NSCLC. Their pooled ORs indicated that HSP27 expres-
sion might be significantly associated with the worse directions for major pathological 
characteristics of NSCLC, including differentiation degree, lymphatic metastasis, TNM 
stage, histological subtypes and tumor size. These pathological parameters were univer-
sally considered to responsible for poor prognosis of NSCLC. Therefore, we speculated 
that such relationship between positive expression of HSP27 and clinicopathological 
characteristics might be able to interpret the prognostic value of HSP27 for 5-year OS 
of NSCLC to some extent, although its validity was still merited to be verified by further 
studies.
Limitations
Finally, several limitations should be seriously considered for accurate interpretations of 
our pooled analyses. First, the estimations on the relationship between HSP27 expres-
sion and clinicopathological characteristics was only based on 714 NSCLC cases from 
eight retrospective observational studies. Similarly, the pooled analysis assessing the 
prognostic roles of HSP27 was only based on 474 NSCLC cases from five retrospec-
tive observational studies. It should be the leading limitation for our meta-analysis 
with including so small number of the current evidences. The validity and accuracy of 
all the integrated estimates should be seriously considered in clinical practices. Second, 
the scarcity of a uniform cut-off definition for positive HSP27 expression might be the 
major confounding factor affecting the validity of this meta-analysis. Moreover, different 
detecting methods supplied by the researchers might cause deviation from the actual 
value to some extent. Third, a significant heterogeneity was revealed between studies 
evaluating the prognostic value of HSP27 for 1-year OS. But we could not identify its 
possible origins by further sensitivity analysis. We speculated that the lack of available 
studies publishing the 1-year survival outcomes might be the main reason for such a 
high heterogeneity. We hope we can collect more convincing outcome data by pooling 
more eligible literatures in the future. Lastly, we found that the majority of enrolled sam-
ples come from China. Clinicians should judiciously evaluate the generality of the com-
bined estimates in the clinical settings of their own nations.
Conclusions
In conclusion, our meta-analysis indicates that HSP27 expression can be an effective 
biomarker for predicting the poor clinicopathological characteristics of NSCLC, includ-
ing the differentiation degree, lymphatic metastasis, TNM stage, histological subtypes 
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and tumor size. Meanwhile, HSP27 expression is also a strong predictor for the poor 
5-year OS in patients with NSCLC. Because of some inherent restrictions in our meta-
analysis, more large-scale studies are urgently required to further confirm these findings, 
and provide more comprehensive evidences to assess the impact of HSP27 up-regulation 
on short-term and long-term survival outcomes of NSCLC in the future.
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